Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 4
1998 9
1999 10
2000 4
2001 9
2002 22
2003 10
2004 22
2005 24
2006 18
2007 14
2008 15
2009 17
2010 24
2011 39
2012 51
2013 76
2014 95
2015 140
2016 135
2017 167
2018 192
2019 192
2020 193
2021 224
2022 227
2023 262
2024 265
2025 291
2026 228
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,709 results

Results by year

Filters applied: . Clear all
Page 1
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Noble PW, et al. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. Lancet. 2011. PMID: 21571362 Clinical Trial.
In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. ...Mean change in percentage FVC in the pirfen …
In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in stud …
Pirfenidone.
[No authors listed] [No authors listed] 2025 Apr 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2025 Apr 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644078 Free Books & Documents. Review.
Pirfenidone is an orally available pyridinone derivative that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during pirfenidone therapy are not uncommon, but it has yet to be implicated in cases of c …
Pirfenidone is an orally available pyridinone derivative that inhibits collagen formation and is used to treat idiopathic pulmonary f …
Pirfenidone.
Lasky J. Lasky J. IDrugs. 2004 Feb;7(2):166-72. IDrugs. 2004. PMID: 15057662 Review.
Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis....
Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including r …
Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR, Martinez FJ, Noth I. Kim JS, et al. Chest. 2024 May;165(5):1163-1173. doi: 10.1016/j.chest.2023.11.035. Epub 2023 Nov 27. Chest. 2024. PMID: 38030064 Free PMC article. Clinical Trial.
RESULTS: Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or nintedanib (n = 143, 35%). The pirfenidone group had more participants with a history of coronary artery disease than the nintedanib g …
RESULTS: Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or n …
Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Kou M, Jiao Y, Li Z, Wei B, Li Y, Cai Y, Wei W. Kou M, et al. Eur J Clin Pharmacol. 2024 Oct;80(10):1445-1460. doi: 10.1007/s00228-024-03720-7. Epub 2024 Jul 4. Eur J Clin Pharmacol. 2024. PMID: 38963453
After 12 months of treatment, the change from baseline in percent predicted FVC (%FVC) was - 0.75% for pirfenidone and - 1.43% for nintedanib. The change from baseline in percent predicted DLCO (%DCLO) was - 2.32% for pirfenidone and - 3.95% for nintedanib. The inci …
After 12 months of treatment, the change from baseline in percent predicted FVC (%FVC) was - 0.75% for pirfenidone and - 1.43% for ni …
Pirfenidone as a novel cardiac protective treatment.
Aimo A, Spitaleri G, Panichella G, Lupón J, Emdin M, Bayes-Genis A. Aimo A, et al. Heart Fail Rev. 2022 Mar;27(2):525-532. doi: 10.1007/s10741-021-10175-w. Epub 2021 Oct 20. Heart Fail Rev. 2022. PMID: 34671871 Free PMC article. Review.
There is some evidence that pirfenidone has antifibrotic activity in various animal models of cardiac disease. Furthermore, the positive results of the PIROUETTE trial, evaluating pirfenidone in patients with HF with preserved ejection fraction, have been very recen …
There is some evidence that pirfenidone has antifibrotic activity in various animal models of cardiac disease. Furthermore, the posit …
Pirfenidone-induced Eosinophilic Pleurisy.
Hase I, Yamaguchi B, Takizawa H, Arakawa H, Sakuma H, Fujiu K, Miyamoto H, Ishii Y. Hase I, et al. Intern Med. 2017;56(14):1863-1866. doi: 10.2169/internalmedicine.56.7738. Epub 2017 Jul 15. Intern Med. 2017. PMID: 28717083 Free PMC article.
The patient was a 69-year-old man with idiopathic pulmonary fibrosis who was taking pirfenidone. After 7 weeks of treatment, he suffered from left-sided eosinophilic pleurisy. ...This is the first case report of pirfenidone-induced pleurisy....
The patient was a 69-year-old man with idiopathic pulmonary fibrosis who was taking pirfenidone. After 7 weeks of treatment, he suffe …
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study.
Yoon HY, Kim H, Bae Y, Song JW. Yoon HY, et al. Eur Respir J. 2025 Feb 27;65(2):2401484. doi: 10.1183/13993003.01484-2024. Print 2025 Feb. Eur Respir J. 2025. PMID: 39510556
After IPTW, the pirfenidone group showed lower incidence (10.4 versus 27.9 cases per 1000 person-years) than the no pirfenidone group. Landmark analysis at 6 months after IPF diagnosis also showed lower incidence of lung cancer in the pirfenidone group than i …
After IPTW, the pirfenidone group showed lower incidence (10.4 versus 27.9 cases per 1000 person-years) than the no pirfenidone …
Pirfenidone-induced photolichenoid drug eruption.
Dwivedi N, Witherspoon J, Yong-Gee S. Dwivedi N, et al. Australas J Dermatol. 2023 May;64(2):299-301. doi: 10.1111/ajd.14010. Epub 2023 Feb 20. Australas J Dermatol. 2023. PMID: 36808729 No abstract available.
2,709 results